**IPO activity remains robust into late 2026, with 254 U.S. listings year-to-date as of mid-October and additional deals scheduled through year-end.** Biotech offerings dominate near-term flow, including Iambic Therapeutics (IAM) pricing October 14–15 at a $15–17 range and City Therapeutics (CTY) the following day at $17–19, both on Nasdaq. Broader market dynamics feature elevated Treasury yields near multi-year highs and selective investor demand, which have prompted some postponements yet supported continued pricing in life sciences and select AI-adjacent names. Recent filings and pipeline reports point to further activity into November, including potential larger debuts, while macroeconomic factors such as Fed policy and equity volatility will influence timing. Traders monitor upcoming earnings seasons, regulatory windows, and benchmark index levels for signals on sustained access to public markets before December 31.